Granzer Regulatory Consulting & Services GmbH, based in Munich, is a consulting firm in drug development and regulatory affairs that manages the full process from idea to approval for pharmaceuticals and medical devices. The company has provided services since 2001 to more than 1,000 clients in Europe, North America, Japan, Australia and Asia. Annually the firm supports over 300 Scientific Advice meetings with FDA, EMA and national authorities and in recent years has managed between five and ten marketing authorization applications (MAA, NDA, BLA) per year through to approval. The staff includes experienced consultants in chemistry/pharmacy, preclinical, clinical, regulatory affairs, medical writing, eCTD, medical devices and project management and the company has access to an established network of specialist advisors. Granzer Regulatory Consulting & Services GmbH is a family business.
Erbringung von Dienstleistungen im Zusammenhang mit Entwicklung und den regulatorischen Anforderungen bei Arzneimitteln und Medizinprodukten soweit dazu keine behördlichen Genehmigungen oder Zulassungen erforderlich sind.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) München Local Court, HRB 265666 (as of 3 November 2026)
| Name | Type | City |
|---|---|---|
| Ulrich Granzer | Geschäftsführer(in) | München |
| Jens Schletter | Geschäftsführer(in) | Rosenheim |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 265666 (as of 3 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | €22,358,206 | €3,115,927 | €25,188,873 | 48 |
| 2024 | €24,809,320 | €4,081,187 | €22,438,400 | 48 |
| 2023 | Rohergebnis€17.3M2 | €3,613,633 | €19,262,762 | 40 |
| 2022 | Rohergebnis€15.1M2 | €2,789,958 | €14,550,894 | 41 |
| 2021 | Rohergebnis€13.7M2 | €3,434,788 | €13,781,835 | 39 |
| 2020 | Rohergebnis€13.5M2 | €4,325,063 | €8,692,816 | 33 |
| 2019 | — | — | €3,140,263 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) München Local Court, HRB 265666 (as of 3 November 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €12,009,802 | 73.7% |
| Material Costs | €4,142,947 | 25.4% |
| Depreciation | €132,796 | 0.8% |
| Interest & Similar | €2,968 | 0.0% |
